Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration

This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Myocardial Infarction

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

KIMHYUNSOO Clinic

Seoul, Gangnam, 06017, South Korea

Location status: Recruiting

About this study

To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Those who had administered Hearticellgram-AMI
Those who voluntarily agreed in writing to participate in this investigation

Exclusion criteria

Treatment and study plan

Hearticellgram-AMI

Biological

Patients who had administered Hearticellgram-AMI.

Primary outcomes

Rate of AESI

Time frame: For 5 years

death, neoplasms or malignancies in tissues or organs, Immune response

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Pharmicell Co., Ltd.

Industry

Registry information

Official study title

Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction

Important dates

Study start: 2022
Primary completion: 2028
Study completion: 2032
First posted: Feb 10, 2026
Registry last updated: Feb 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting